Therefore, wondering whether the outcome effect of DNMT3A mutation/SNP on AML could act through affecting DNMT3A mRNA expression, we determined DNMT3A transcript levels in PBMCs from de novo AML patients. This evidence concerns the gene DNMT3A and acute myeloid leukemia.